癌症基因治療市場規模、佔有率、成長分析、按療法、按適應症、按最終用戶、按地區 - 行業預測，2024-2031

2022年癌症基因治療市場規模估值為23.8億美元，從2023年的28.6億美元成長到2031年的126.3億美元，預測期（2024-2031）的複合年成長率預計將保持在20.42%。

在基因研究和治療策略進步的推動下，癌症基因治療市場正在經歷強勁成長。基因療法透過針對疾病根本原因的精確基因干預，為治療癌症提供了一條有前景的途徑。推動這一成長的因素包括全球癌症發病率上升、對個人化治療選擇的需求不斷增加以及擴大採用基因療法作為可行的治療方法。此外，持續的研究和開發計劃、支持性法規結構以及與學術和製藥部門的合作關係正在支持市場擴張。儘管面臨治療成本上升和監管複雜性等挑戰，持續的技術創新和對癌症遺傳學的深入了解預計將推動基因治療的進一步進步，為市場帶來光明的前景。

目錄

介紹

• 這項研究的目的
• 定義
• 市場範圍

調查方法

• 資訊採購
• 二手資料來源和主要資料來源
• 市場規模預測
• 市場假設與限制

執行摘要

• 市場概況展望
• 供需趨勢分析
• 按細分市場的機會分析

市場動態及展望

• 市場動態
  • 促進因素
  • 機會
  • 抑制因素
  • 任務
• 波特的分析

主要市場考察

• 成功的關鍵因素
• 競爭程度
• 監管分析
• 專利分析
• SWOT分析
• 贖回和監管場景
• 主要投資機會
• 管道分析
• 臨床實驗
• 市場吸引力指數
• 市場生態系統
• 案例研究

癌症基因治療市場：依治療分類

• 市場概況
• 基因誘導免疫療法
• 溶瘤病毒療法
• 基因轉移

癌症基因治療市場：依適應症分類

• 市場概況
• 乳癌
• 卵巢癌
• 肝癌
• 胰臟癌
• 肺癌
• 攝護腺癌
• 其他

癌症基因治療市場：依最終用戶分類

• 市場概況
• 醫院
• 診斷中心
• 研究機構
• 其他

癌症基因治療市場：按地區分類的規模

• 市場概況
• 北美洲
  • 美國
  • 加拿大
• 歐洲
  • 德國
  • 西班牙
  • 法國
  • 義大利
  • 英國
  • 其他歐洲國家地區
• 亞太地區
  • 中國
  • 印度
  • 日本
  • 韓國
  • 其他亞太地區
• 拉丁美洲
  • 巴西
  • 其他拉丁美洲地區
• 中東和非洲 (MEA)
  • 海灣合作理事會國家
  • 南非
  • 其他中東/非洲地區

競爭格局

• 前5名企業對比
• 主要企業市場定位（2023年）
• 主要市場參與者所採取的策略
• 近期市集活動
• 主要企業市場佔有率（2023年）

主要企業簡介

• Novartis AG（Switzerland）
• Biogen Inc.（US）
• Gilead Sciences, Inc.（US）
• Bristol-Myers Squibb（US）
• Rocket Pharmaceuticals（USA）
• Sarepta Therapeutics, Inc.（US）
• Vertex Pharmaceuticals（USA）
• Verve Therapeutics（USA）
• Voyager Therapeutics（USA）
• Johnson & Johnson（USA）
• AstraZeneca（UK）
• GlaxoSmithKline plc（UK）
• Celgene Corporation（USA）
• Bluebird bio Inc（USA）
• Amgen Inc.（USA）
• Alnylam Pharmaceuticals, Inc.（US）
• Merck & Co., Inc.（USA）
• Adaptimmune Therapeutics plc（UK）
• Euroscreen SA（Belgium）
• Vicore Pharma AB（Sweden）

Cancer Gene Therapy Market size was valued at USD 2.38 billion in 2022 and is poised to grow from USD 2.86 billion in 2023 to USD 12.63 billion by 2031, growing at a CAGR of 20.42% in the forecast period (2024-2031).

The market for cancer gene therapy is experiencing robust growth, propelled by advancements in genetic research and therapeutic strategies. Gene therapy offers a promising avenue for treating cancer through precise genetic interventions, targeting the underlying causes of the disease. Factors driving this growth include the rising global incidence of cancer, increasing demand for personalized treatment options, and expanding adoption of gene therapy as a viable treatment modality. Furthermore, ongoing research and development initiatives, supportive regulatory frameworks, and collaborations between academic and pharmaceutical sectors are bolstering market expansion. Despite challenges like high treatment costs and regulatory complexities, continuous innovation and deeper insights into cancer genetics are anticipated to drive further advancements in gene therapy, promising a brighter outlook for the market ahead.

Top-down and bottom-up approaches were used to estimate and validate the size of the Cancer Gene Therapy Market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Cancer Gene Therapy Market Segmental Analysis

The Cancer Gene Therapy market is segmented into segments i.e. by Therapy, Indication, End User and region. Based on Therapy, it is divided into Gene Induced Immunotherapy, Oncolytic Virotherapy, and Gene Transfer. Based on Indication, the market is segmented into Breast Cancer, Ovarian Cancer, Liver Cancer, Pancreatic Cancer, Lung Cancer, Prostate Cancer, and Others. Based on End Users the market is further segmented into Hospitals, Diagnostic centres, Research Institutes, and Others. Based on region, the market is segmented into North America, Europe, Asia Pacific, Middle East and Africa, and Latin America.

Drivers of the Cancer Gene Therapy Market

The cancer gene therapy market is driven by the growing global burden of cancer, which has spurred demand for more effective treatments. This trend stems from the escalating incidence of diverse cancer types, prompting the exploration and uptake of gene therapy strategies. Gene therapy for cancer holds promise in directly addressing specific genetic mutations underlying tumour development, thereby offering personalized and precise therapeutic solutions. This momentum is reinforced by continuous advancements in gene editing technologies and deeper insights into cancer genetics, facilitating the refinement and enhancement of therapeutic approaches. These factors collectively fuel the expansion and innovation within the field of cancer gene therapy.

Restraints in the Cancer Gene Therapy Market

A significant limitation in the global cancer gene therapy market stems from the intricate and challenging nature of gene therapy itself. This therapeutic approach necessitates the introduction of therapeutic genes into patient cells, a process fraught with technical complexities that can impact safety, effectiveness, and the sustainability of outcomes over time. Moreover, regulatory and ethical concerns, alongside the substantial expenses involved in research, development, and commercialization, further impede the widespread implementation of cancer gene therapy solutions. These combined factors present barriers to market expansion, underscoring the imperative for continued research and developmental efforts aimed at surmounting these obstacles and enhancing the viability of gene therapy as a treatment modality for cancer.

Market Trends of the Cancer Gene Therapy Market

A significant trend in the global cancer gene therapy market is the increasing emphasis on personalized and targeted treatments. This approach involves modifying cancer cells' genes to either inhibit their growth or stimulate the immune system's response against them. Advancements in genetic sequencing and molecular diagnostics enable researchers to pinpoint specific genetic abnormalities within individual patients' tumours. This knowledge is crucial as it facilitates the development of personalized gene therapies designed to target these specific genetic mutations or pathways. Tailoring treatments according to each patient's unique genetic profile holds promise for enhancing treatment efficacy and reducing adverse effects. Ultimately, personalized gene therapy represents a more precise and efficient strategy in the fight against cancer, potentially transforming treatment outcomes on an individualized basis.

Table of Contents

Introduction

• Objectives of the Study
• Definitions
• Market Scope

Research Methodology

• Information Procurement
• Secondary & Primary Data Sources
• Market Size Estimation
• Market Assumptions & Limitations

Executive Summary

• Market Overview Outlook
• Supply Demand Trend Analysis
• Segmental Opportunity Analysis

Market Dynamics & Outlook

• Market Dynamics
  • Drivers
  • Opportunities
  • Restraints
  • Challenges
• Porters Analysis
  • Competitive rivalry
  • Threat of Substitute Products
  • Bargaining Power of Buyers
  • Threat of New Entrants
  • Bargaining Power of Suppliers

Key Market Insights

• Key Success Factors
• Degree of Competition
• Regulatory Analysis
• Patent Analysis
• SWOT Analysis
• Reimbursement & Regulatory Scenario
• Top Investment Pockets
• Pipeline Analysis
• Clinical Trail
• Market Attractiveness Index
• Market Ecosystem
• Case Study

Cancer Gene Therapy Market by Therapy

• Market Overview
• Gene Induced Immunotherapy
• Oncolytic Virotherapy
• Gene Transfer

Cancer Gene Therapy Market by Indication

• Market Overview
• Breast Cancer
• Ovarian Cancer
• Liver Cancer
• Pancreatic Cancer
• Lung Cancer
• Prostate Cancer
• Others

Cancer Gene Therapy Market by End User

• Market Overview
• Hospitals
• Diagnostic Centers
• Research Institutes
• Others

Cancer Gene Therapy Market Size by Region

• Market Overview
• North America
  • USA
  • Canada
• Europe
  • Germany
  • Spain
  • France
  • Italy
  • UK
  • Rest of Europe
• Asia Pacific
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America
  • Brazil
  • Rest of Latin America
• Middle East & Africa (MEA)
  • GCC Countries
  • South Africa
  • Rest of MEA

Competitive Landscape

• Top 5 Player Comparison
• Market Positioning of Key Players, 2023
• Strategies Adopted by Key Market Players
• Recent Activities in the Market
• Key Companies Market Share (%), 2023

Key Company Profiles

• Novartis AG (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Biogen Inc. (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Gilead Sciences, Inc. (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Bristol-Myers Squibb (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Rocket Pharmaceuticals (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Sarepta Therapeutics, Inc. (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Vertex Pharmaceuticals (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Verve Therapeutics (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Voyager Therapeutics (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Johnson & Johnson (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• AstraZeneca (UK)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• GlaxoSmithKline plc (UK)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Celgene Corporation (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Bluebird bio Inc (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Amgen Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Alnylam Pharmaceuticals, Inc. (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Merck & Co., Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Adaptimmune Therapeutics plc (UK)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Euroscreen S.A. (Belgium)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Vicore Pharma AB (Sweden)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments